Nurix Therapeutics (NASDAQ:NRIX – Get Free Report)‘s stock had its “buy” rating reissued by BTIG Research in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $32.00 price target on the stock. BTIG Research’s target price suggests a potential upside of 29.61% from the stock’s current price.
A number of other brokerages also recently commented on NRIX. HC Wainwright reiterated a “buy” rating and issued a $34.00 price objective (up from $32.00) on shares of Nurix Therapeutics in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Tuesday, April 21st. Needham & Company LLC restated a “buy” rating and issued a $34.00 target price on shares of Nurix Therapeutics in a research note on Monday, June 15th. Oppenheimer started coverage on Nurix Therapeutics in a research report on Monday, June 29th. They issued an “outperform” rating and a $28.00 target price for the company. Finally, Jefferies Financial Group lifted their price target on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, June 8th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $33.00.
Read Our Latest Report on Nurix Therapeutics
Nurix Therapeutics Price Performance
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last announced its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.09). Nurix Therapeutics had a negative net margin of 411.37% and a negative return on equity of 64.21%. The company had revenue of $9.04 million for the quarter, compared to analyst estimates of $15.29 million. As a group, sell-side analysts expect that Nurix Therapeutics will post -2.88 earnings per share for the current fiscal year.
Insider Activity
In other news, insider Gwenn Hansen sold 5,394 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.00, for a total value of $107,880.00. Following the sale, the insider directly owned 115,005 shares in the company, valued at approximately $2,300,100. This represents a 4.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 14,055 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total value of $233,313.00. Following the completion of the sale, the chief financial officer owned 37,592 shares in the company, valued at approximately $624,027.20. This represents a 27.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,051 shares of company stock valued at $434,466 in the last three months. Company insiders own 6.70% of the company’s stock.
Institutional Trading of Nurix Therapeutics
Several institutional investors have recently bought and sold shares of the stock. General Atlantic L.P. acquired a new stake in shares of Nurix Therapeutics during the fourth quarter worth approximately $92,899,000. Vanguard Group Inc. boosted its holdings in shares of Nurix Therapeutics by 32.5% in the 4th quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock worth $112,862,000 after acquiring an additional 1,460,736 shares in the last quarter. Baker BROS. Advisors LP boosted its holdings in shares of Nurix Therapeutics by 20.0% in the 4th quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company’s stock worth $88,373,000 after acquiring an additional 776,431 shares in the last quarter. Flax Pond Capital LLC bought a new stake in Nurix Therapeutics during the 4th quarter worth approximately $1,521,000. Finally, Perceptive Advisors LLC grew its position in Nurix Therapeutics by 151.1% during the 4th quarter. Perceptive Advisors LLC now owns 3,555,877 shares of the company’s stock worth $67,455,000 after acquiring an additional 2,139,728 shares during the last quarter.
Nurix Therapeutics Company Profile
Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.
The company’s pipeline includes multiple programs in various stages of development.
Featured Articles
- Five stocks we like better than Nurix Therapeutics
- PepsiCo’s Dividend Could Turn Patience Into Real Profit
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
